142 related articles for article (PubMed ID: 9596278)
1. Prognostic markers in pheochromocytoma.
Clarke MR; Weyant RJ; Watson CG; Carty SE
Hum Pathol; 1998 May; 29(5):522-6. PubMed ID: 9596278
[TBL] [Abstract][Full Text] [Related]
2. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Gupta D; Shidham V; Holden J; Layfield L
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
[TBL] [Abstract][Full Text] [Related]
4. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
5. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
6. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
[TBL] [Abstract][Full Text] [Related]
8. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 staining in pheochromocytomas.
Fogt F; Tomaszewski JE; Vortmeyer AO; Poremba C
Hum Pathol; 1999 Apr; 30(4):486-7. PubMed ID: 10208474
[No Abstract] [Full Text] [Related]
10. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
11. Differential heparanase-1 expression in malignant and benign pheochromocytomas.
Quiros RM; Kim AW; Maxhimer J; Gattuso P; Xu X; Prinz RA
J Surg Res; 2002 Nov; 108(1):44-50. PubMed ID: 12443714
[TBL] [Abstract][Full Text] [Related]
12. Pheochromocytomas: can malignant potential be predicted?
John H; Ziegler WH; Hauri D; Jaeger P
Urology; 1999 Apr; 53(4):679-83. PubMed ID: 10197840
[TBL] [Abstract][Full Text] [Related]
13. [Distinction between benign and malignant pheochromocytomas].
Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas.
Nagura S; Katoh R; Kawaoi A; Kobayashi M; Obara T; Omata K
Mod Pathol; 1999 Dec; 12(12):1107-11. PubMed ID: 10619262
[TBL] [Abstract][Full Text] [Related]
15. Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma.
Saffar H; Sanii S; Heshmat R; Haghpanah V; Larijani B; Rajabiani A; Azimi S; Tavangar SM
Am J Clin Pathol; 2011 Mar; 135(3):454-60. PubMed ID: 21350102
[TBL] [Abstract][Full Text] [Related]
16. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?
van der Harst E; Bruining HA; Jaap Bonjer H; van der Ham F; Dinjens WN; Lamberts SW; de Herder WW; Koper JW; Stijnen T; Proye C; Lecomte-Houcke M; Bosman FT; de Krijger RR
J Pathol; 2000 Jun; 191(2):175-80. PubMed ID: 10861578
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic role of inhibin α-subunit and inhibin/activin β-subunit in adrenal cortical and medullary tumors in Egyptian patients.
Elmoneim HM; Samaka RM; Ali H
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):462-9. PubMed ID: 22417854
[TBL] [Abstract][Full Text] [Related]
18. Multimodality imaging findings of pheochromocytoma with associated clinical and biochemical features in 53 patients with histologically confirmed tumors.
Raja A; Leung K; Stamm M; Girgis S; Low G
AJR Am J Roentgenol; 2013 Oct; 201(4):825-33. PubMed ID: 24059371
[TBL] [Abstract][Full Text] [Related]
19. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
20. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
